Skip to main content

Table 2 Clinical characteristics according to the level of FAR

From: The association between fibrinogen-to-albumin ratio (FAR) and adverse prognosis in patients with acute decompensated heart failure at different glucose metabolic states

Characteristics

FAR-L(FAR < 0.079)

(n=436)

FAR-H(FAR ≥ 0.079)

(n=595)

p Value

Female, n (%)

168 (38.5)

225 (37.8)

0.815

Age (years)

69 (59, 78)

72 (64, 80)

0.097

BMI (kg/m2)

24.5 (21.6, 27.2)

24.0 (21.5, 27.0)

 < 0.001

Heart rate (bpm)

80 (67, 98)

81 (70, 96)

0.126

SBP (mmHg)

127 (114, 142)

130 (115, 146)

0.092

DBP (mmHg)

75 (66,88)

75 (65,86)

0.141

Medical history, n (%)

 Ischemic cardiomyopathy

137 (38.5)

252 (42.5)

 < 0.001

 None-ischemic cardiomyopathy

117 (26.8)

92 (15.5)

 < 0.001

 Valvular heart disease

90 (20.6)

113 (19.0)

0.510

 Atrial fibrillation

210 (48.2)

236 (39.7)

0.006

 Hypertension

238 (54.6)

387 (65.0)

0.001

 Hyperlipidemia

35 (8.0)

53 (8.9)

0.617

Glucose metabolism states

  

0.001

 DM

184 (42.4)

321 (53.9)

 

 Pre-DM

146 (33.5)

163 (27.4)

 

 NGR

106 (24.3)

111 (18.7)

 

Fibrinogen (g/L)

2.4 (2.1, 2.7)

3.5 (3.1, 4.1)

 < 0.001

ALB (g/L)

39.6 (37.2, 41.7)

37.0 (34.2, 39.3)

 < 0.001

FPG (mg/dL)

5.00 (4.58, 5.97)

5.2 (4.58, 6.58)

0.010

HbA1c (%)

6.0 (5.6, 6.7)

6.2 (5.7, 7.1)

0.008

Hemoglobin (g/L)

133 (119, 145)

125 (104, 138)

 < 0.001

BNP (pg/mL)

422.0 (192.0, 990.8)

569.0 (242.0, 1220.0)

0.001

CRP (mg/L)

3.6 (2.5, 5.2)

7.0 (3.6, 24.7)

 < 0.001

Hematocrit (%)

39.5 (35.8, 43.0)

37.7 (31.8, 41.3)

 < 0.001

UA (μmol/L)

423.0 (331.5, 535.8)

437.0 (348.0, 548.0)

0.345

Creatinine (μmol/L)

79.0 (64.5, 100.1)

87.9 (69.0, 123.0)

 < 0.001

Sodium (mmol/L)

138.8 (136.0, 141.6)

138.3 (135.0, 141.4)

0.030

Potassium (mmol/L)

3.9 (3.6, 4.2)

3.9 (3.6, 4.2)

0.725

WBC (× 109/L)

5.9 (4.8,7.0)

6.5 (5.2, 8.3)

 < 0.001

Total cholesterol (mmol/L)

3.63 (3.00, 4.38)

3.59 (2.94, 4.42)

0.751

Triglyceride (mmol/L)

1.00 (0.75, 1.52)

1.01 (0.78, 1.37)

0.455

HDL-C (mmol/L)

1.00 (0.82, 1.23)

0.98 (0.77, 1.14)

0.002

LDL-C (mmol/L)

2.00 (1.54, 2.62)

2.01 (1.43, 2.74)

0.760

AST (U/L)

24.2 (18.3, 34.0)

22.8 (16.7, 33.0)

 < 0.001

ALT (U/L)

20.9 (14.7, 35.9)

17.9 (11.8, 31.0)

0.051

IVSTD (cm)

0.9 (0.8, 1.0)

0.9 (0.8, 1.1)

0.055

LVPWTD (cm)

0.9 (0.8, 1.0)

0.9 (0.8, 1.0)

0.092

LVDD (cm)

6.0 (5.2, 6.8)

5.8 (5.1, 6.5)

0.004

LAD (cm)

5.0 (4.4, 5.4)

4.8 (4.4, 5.2)

0.001

LVEF, n (%)

  

0.064

 ≤ 40

244 (56.0)

291 (48.9)

–

41–49

61(14.0)

106(17.8)

–

 > 50

131(30.0)

198(33.3)

–

Medications at admission, n (%)

 Antiplatelet agent

182(40.1)

273(45.9)

0.186

 ACEI/ARB/ARNI

175(40.1)

231(38.8)

0.670

 Beta-blocker

336(77.1)

471(79.2)

0.420

 Statins

241(55.3)

320(53.8)

0.634

 Diuretics

388(89.0)

526(88.4)

0.769

 Digoxin

50(11.5)

72(12.1)

0.756

 Aldosterone antagonist

175(40.1)

244(41)

0.779

 Insulin

62(14.2)

72(12.1)

0.371

 Metformin

61(14.0)

85(14.3)

0.893

 Sulfonylureas

3(0.7)

6(1.0)

0.585

 SGLT2i

5(1.6)

39(6.6)

0.003

  1. BMI Body mass index; SBP Systolic blood pressure; DBP Diastolic blood pressure; FPG Fasting plasma glucose; FAR Fibrinogen-to-albumin ratio; BNP B-type natriuretic peptide; CRP C-reative protein; ALB Albumin; UA Uric acid; Cr Creatinine; Na Sodium; K Potassium; WBC White blood cell; HDL-C high-density lipoprotein cholesterol; LDL-C Low-density lipoprotein-C; AST Alanine aminotransferase; ALT Aspartate transaminase; IVSTD Interventricular septal thickness at diastole; LVPWTD Left ventricular posterior wall end-diastolic thickness; LVDD Left ventricular end-diastolic diameter; LAD Left atrial diameter; LVEF Left ventricular ejection fraction; ACEI Angiotensin-converting enzyme inhibitor; ARB Angiotensin receptor inhibitor; ARNI Angiotensin receptor neprilysin inhibitor; SGLT2i Sodium-glucose cotransporter 2 inhibitor